# A Multi-Center, Open-Label Study

> **NCT01468259** · PHASE1 · WITHDRAWN · sponsor: **Chelsea Therapeutics**

## Conditions studied

- Renal Disease
- End Stage Renal Disease

## Interventions

- **DRUG:** Droxidopa

## Key facts

- **NCT ID:** NCT01468259
- **Lead sponsor:** Chelsea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468259, "A Multi-Center, Open-Label Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01468259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*